Optimizing the Use of Hydroxychloroquine in the Management of COVID-19 Given Its Pharmacological Profile
Ahmed S. Ali, Mahran S. Abdel-Rahman, Riyadh S. Almalikil, Abir S. Mohamed, Khalid A. Alfaifi, Abdelbabgi El. Fadil, Nagla A. El-Shitany, Huda M. Alkreathy
Journal of Pharmaceutical Research International · pp. 29–43 · Published 29 May 2020
10.9734/jpri/2020/v32i830468Abstract
After the global pandemic of the new coronavirus, its rapid spread and many victims, it is necessary to find an effective vaccine or drugs to overcome it. Most specialists consider that repositioning some medications is the best, fastest and most reliable option for treating patients with the new coronavirus without delay. One of these drugs was an old antimalarial drug, hydroxychloroquine. The current review aimed to explore its potential mechanism, as well as its pharmacokinetics and toxicity, in an attempt to suggest a treatment protocol for its use in treating the COVID-19 virus effectively and safely. This study reviewed the published references on the popular search engines as well as the reference books regarding the pharmacological effects of HCQ. The results of this study suggested the following practical guidelines to optimize HCQ efficacy and safety in the management of COVID-19. HQC should be used as early as possible, i.e., once the viral infection is confirmed or suspected. A loading dose is recommended to be given in 3-4 divided doses to minimize cardiac toxicity. Maintenance daily dose (divided into two doses), should be continued until complete remission. Precautions, drug-interaction, contraindications, variable metabolic pathways in the particular population should be considered. This study suggests more clinical trials regarding the use of HCQ in the management of early identified COVID-19 patients under close medical observation to minimize HCQ cardiac toxicity.
Cited by 12
H. Amal, A. Mohamed, M. O. Abdel-Halim · European Journal of Clinical Pharmacology · 2026
A. Ajala, A. Uzairu, Gideon Adamu Shallangwa · Biocatalysis and Agricultural Biotechnology · 2023
Isabela Landsteiner de Sampaio Amêndola, Jonathan Aires Pinheiro, P. Póvoa · Journal of Clinical Medicine · 2022
A. Ali, Mohsen G Alrashedi, O. Ahmed · Polymers · 2022
Mohsen G Alrashedi, Ahmed Geza. Alrashedi, A. Ali · Journal of Pharmaceutical Research International · 2021
A. Ali, Ibrahim M. Ibrahim, Abdulhadi S Burzangi · Arabian Journal of Chemistry · 2021
L. Anedda, L. Bianchini, L. Cuzzolin · European Review for Medical and Pharmacological Sciences · 2021
Mohammad Salem Hareedy, S. Rashad, H. Hetta · Drug Metabolism and Drug Interactions · 2021
Mohammad Salem Hareedy, S. Rashad, H. Hetta · Drug Metabolism and Personalized Therapy · 2021
R. Hussein, H. M. Elkhair · Journal of Molecular Structure · 2021
Related research
- Covid-2019:“A Microbiological Monster” — shares topic coverage
- COVID 19 Disease Caused by Coronavirus 2 (SARS-CoV-2) (Severe Acute Respiratory Syndrome) — shares topic coverage
- Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): What Can Africa Learn from Ongoing Research in Epidemiology, Clinical Manifestations, Chemotherapy and Prevention? — shares topic coverage
- Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19 — shares topic coverage
- Early Treatment with Hydroxychloroquine Improves Clinical Outcomes and Reduces Hospital Admissions in COVID-19 Associated Pneumonia — shares topic coverage
Article metrics
Real usage data collected on this platform.
0
Page views
0
PDF downloads
0
Outbound clicks
12
Citations
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
No views recorded yet.
Traffic sources
Referring site, by host.
No traffic recorded yet.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.